Whitehawk Therapeutics (WHWK) Corporate presentation summary

Differentiated ADC platform and leadership

• Portfolio includes three ADC assets licensed from Wuxi Biologics, with novel linker-payload technology from Hangzhou DAC.

• Two clinical-stage assets and one IND expected by mid-2026.

• Founding team and board have deep ADC and industry experience.

• Cash position of $123 million as of March 31, 2026, with runway into 2028.

• Backed by blue-chip biotech investors.

Optimized ADC technology and preclinical data

• Platform features high-affinity antibody selection, attenuated Fc region, and proprietary TOP1 inhibitor payload.

• Demonstrates 3-10x greater potency and 5-25x more stability than average TOP1 ADCs in preclinical models.

• Safety margin is 2-3x higher in non-severely toxic doses in monkeys.

Portfolio and clinical strategy

• Three assets: HWK-007 (PTK7), HWK-016 (MUC16), HWK-206 (SEZ6), targeting multiple solid tumor indications.

• HWK-007 and HWK-016 focus on lung, ovarian, and endometrial cancers; HWK-206 targets SCLC, CNS tumors, and neuroendocrine neoplasms.

• First clinical data readouts for HWK-007 and HWK-016 anticipated in 1H 2027.

• IND for HWK-206 expected by mid-2026, with Phase 1 planned for SCLC and NENs.